ATHA - יחס חוב להיוון בספרים Athira Pharma Inc

Athira Pharma, Inc. (ATHA) is developing advanced neural connection regeneration methods to combat Parkinson's and Alzheimer's diseases. The immense potential of this market drives colossal demand for new pharmaceuticals. The company's revenue is based on the commercialization of small molecules for brain restoration. Analyzing this chart on GURU.Markets, we see that the debt-to-capitalization ratio is 0.03.

Assess the financial stability of Athira Pharma, Inc. (ATHA) through the balance of debt and equity. This metric compares total liabilities to the book value of equity to determine the degree of leverage. By analyzing the current ratio of liabilities to book capitalization, an investor can discern the business's level of dependence on creditors. For an innovator in neuron regeneration, low debt is critically important, as it ensures the autonomy of costly Alzheimer's disease research.